Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
Retrieved on:
Wednesday, January 12, 2022
Clinical trial, Vaccination, LNP, Peking Union Medical College, Vaccine, R, Disease, COVID-19, Safety, Adult, Immunization, Prevention, DEC Systems Research Center, Quality control, CAS, Public health, AIM, Chinese Academy of Medical Sciences COVID-19 vaccine, Chinese Center for Disease Control and Prevention, Efficiency, Hospital, Tsinghua University, Wuhan Institute of Virology, Fudan University, Infection, Medicine, Institute, Polio, Institute of Biomedical Science, RNA transfection, Coronavirus, III, GMT, Virology
Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
Key Points:
- Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
- Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
- At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
- At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.